ArriVent to Present Initial Phase 1 ARR-217 Data at ESMO 2026
ArriVent says it will present initial safety and efficacy data from the Phase 1 ARR-217 study in gastrointestinal cancers at ESMO 2026. A webinar is scheduled for Oct. 26 at 8 a.m. ET.
ArriVent says it will present initial safety and efficacy data from the Phase 1 ARR-217 study in gastrointestinal cancers at ESMO 2026. A webinar is scheduled for Oct. 26 at 8 a.m. ET.